Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2023-04-23 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
关于拟续聘上会会计师事务所（特殊普通合伙）担任公司2023年外部审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an external audit firm for the fiscal year 2023. It details the qualifications, independence, and fees of the audit firm, as well as approvals from the audit committee, independent directors, and the board of directors. There are no actual financial statements or audit reports included, only information about the appointment process and related approvals. The document length is 3710 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information (AR) type, since it relates specifically to audit matters and the appointment of the auditor, but does not contain the full annual report or audit report itself. FY 2023
2023-04-23 Chinese
2022年度独立董事述职报告（姜明辉）
Board/Management Information Classification · 95% confidence The document is titled '2022 年度独立董事述职报告' which translates to '2022 Annual Independent Director's Work Report'. It details the independent director's attendance at board meetings, opinions on company matters, participation in committees, and efforts to protect investor rights during the 2022 fiscal year. The content focuses on governance, director duties, and compliance with laws and company rules. There is no financial data or financial statements presented, nor is it an announcement of a report publication. The document is a detailed report on board/management activities and governance from the perspective of an independent director. Therefore, it fits best under 'Board/Management Information (MANG)' which covers announcements of changes or reports related to the company's board or senior management activities.
2023-04-23 Chinese
内部控制审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report". It includes detailed information about the company's internal control evaluation, audit opinions on the effectiveness of internal controls over financial reporting as of December 31, 2022, and a self-evaluation report on internal controls. The document is issued by a certified public accounting firm and addresses the shareholders. It discusses audit responsibilities, internal control scope, evaluation criteria, and conclusions about the absence of material weaknesses or significant deficiencies in internal controls. This is a standalone audit report focused on internal control over financial reporting, not a full annual report or other types of filings. Therefore, it fits the category of Audit Report / Information (AR). The document length (10,386 characters) and content confirm it is a full report, not just an announcement or certification letter. FY 2022
2023-04-23 Chinese
2022年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2022年度董事会工作报告' which translates to '2022 Annual Board of Directors Work Report'. It details the activities, meetings, and resolutions of the board of directors throughout the year 2022, including the number of meetings, agenda items, and compliance with laws and regulations. It also outlines the board's work plan for 2023. The content focuses on the board's governance, oversight, and operational activities rather than financial results or audit opinions. There is no indication that this is a full annual report (10-K) or an audit report (AR). It is not a simple announcement or a proxy statement but a detailed report on board activities and governance. Therefore, the document fits best under the category of Board/Management Information (MANG), which covers announcements of changes and reports related to the company's board and senior management activities.
2023-04-23 Chinese
关于持股5%以上股东一致行动人增持公司股份超过1%的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a shareholder (沈臻宇 and associated entities) increasing their shareholding in the company Harbin Yuheng Pharmaceutical Co., Ltd. by more than 1%, specifically a 1.60% increase via block trades. It details the shareholding changes, the method of transaction, and compliance with relevant securities laws. There is no financial statement, management discussion, or report content. The document is a notification of a major shareholding change, fitting the definition of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a report or announcement of a report publication.
2023-04-12 Chinese
关于使用闲置自有资金进行委托理财的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the progress of using idle self-owned funds for entrusted financial management. It includes specifics about various financial products purchased, amounts, risk ratings, investment scope, and risk control measures. The document is an update on the company's financing activities related to the use of idle funds in financial products, rather than a full financial report, earnings release, or management discussion. It does not contain comprehensive financial statements or quarterly/yearly results but focuses on capital usage and investment updates. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is sufficient and detailed, confirming it is not a mere announcement of a report but a substantive update on financing activities.
2023-04-06 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.